Retrospective analysis of "real world data" of pediatric oncological patients after treatment with the commercially available BiTE antibody Blincyto (Blinatumomab)

Retrospective analysis of "real world data" of pediatric oncological patients after treatment with the commercially available BiTE antibody Blincyto (Blinatumomab) - BlinaPed

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037292

Enrollment

Registered

2025-08-07

Start date

2024-09-01

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C91.0

Interventions

Group 1: The first observational group consists of patient that were treated in the pediatric clinic of the Dr. von Haunerschen pediatric hospital in the time between 2015 and 2022 with Blinatumomab i

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: treatment with Blinatumomab in the pediatric clinic of the Dr. von Haunerschen pediatric hospital in the time between 2015 and 2022

Exclusion criteria

Exclusion criteria: treatment with Blinatumomab dosages other than 15 or 30 µg/m2/day

Design outcomes

Primary

Measure	Time frame
Does treatment with Blinatumomab in a dosage of 30 µg/m2/day aggravate the adverse events in comparison to the standard dosage of 15 µg/m2/day?	—

Secondary

Measure	Time frame
Are there any indications that a higher dose of blinatumomab contributes to better leukemia control?	—

Countries

Germany

Contacts

Public ContactChristian Braun

Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital

Chr.Braun@med.uni-muenchen.de+4989440052843

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026